Tirzepatide: difference between revisions
Diff·revision 19 → 20·21:58, 14 Apr 2025
Difference between revision 19 and revision 20 of Tirzepatide. 3 lines changed; the page grew by 243 bytes.
| Revision 19 — 22:20, 26 Mar 2025 NNT_Nerys (talk) rm duplicated pharmacokinetics — the same figures appear in the infobox 6,329 bytes ±0 | Revision 20 — 21:58, 14 Apr 2025 ArchiveBot (talk) bot: expand DOI to full citation 6,572 bytes +243 | ||
|---|---|---|---|
| 54 | Gallbladder events, injection-site reactions and a small resting heart-rate increase are all reported. The label carries the class contraindication in personal or family history of medullary thyroid carcinoma. Hypoglycaemia is uncommon in monotherapy and becomes relevant when the drug is combined with insulin or a sulfonylurea, in which case the background agent is usually reduced. | 54 | Gallbladder events, injection-site reactions and a small resting heart-rate increase are all reported. The label carries the class contraindication in personal or family history of medullary thyroid carcinoma. Hypoglycaemia is uncommon in monotherapy and becomes relevant when the drug is combined with insulin or a sulfonylurea, in which case the background agent is usually reduced. |
| 55 | 55 | ||
| + | 56 | The five-step escalation from 2.5 mg with four weeks at each step exists for tolerability rather than efficacy, and compressing it predictably increases gastrointestinal events. See [[Dose escalation schedule]]. | |
| + | 57 | ||
| 56 | == References == | 58 | == References == |
| 57 | {{reflist}} | 59 | {{reflist}} |
| ⋮ | ⋮ | ||
| 66 | * [[Glucose-dependent insulinotropic polypeptide]] | 68 | * [[Glucose-dependent insulinotropic polypeptide]] |
| 67 | * [[SURMOUNT trial programme]] | 69 | * [[SURMOUNT trial programme]] |
| + | 70 | * [[SURPASS trial programme]] | |
| 68 | 71 | ||
| 69 | {{DEFAULTSORT:Tirzepatide}} | 72 | {{DEFAULTSORT:Tirzepatide}} |